NovaQuest Capital Management Acquires CutisPharma, Inc.
WILMINGTON, Mass. (Mar. 26, 2018) – CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with its recently approved 505(b)(2) NDA for FIRVANQ ™ vancomycin oral solution kit by the FDA, today announced that it has been acquired by NovaQuest Capital Management, L.L.C. (“NovaQuest”). As a part of the transaction, Goldman Sachs Specialty Lending Group has provided financing to further support CutisPharma’s growth requirements. Financial terms were not disclosed. TAP Advisors acted as financial advisor to CutisPharma.